Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ZTS 
Zoetis Inc (ZTS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/17/2025: ZTS (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
19 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $195.04
1 Year Target Price $195.04
| 10 | Strong Buy |
| 4 | Buy |
| 5 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -10.94% | Avg. Invested days 48 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/17/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 69.43B USD | Price to earnings Ratio 27.95 | 1Y Target Price 195.04 |
Price to earnings Ratio 27.95 | 1Y Target Price 195.04 | ||
Volume (30-day avg) 19 | Beta 0.94 | 52 Weeks Range 139.22 - 198.58 | Updated Date 06/30/2025 |
52 Weeks Range 139.22 - 198.58 | Updated Date 06/30/2025 | ||
Dividends yield (FY) 1.28% | Basic EPS (TTM) 5.58 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 27.12% | Operating Margin (TTM) 38.11% |
Management Effectiveness
Return on Assets (TTM) 15.11% | Return on Equity (TTM) 52.09% |
Valuation
Trailing PE 27.95 | Forward PE 25.19 | Enterprise Value 74460195865 | Price to Sales(TTM) 7.48 |
Enterprise Value 74460195865 | Price to Sales(TTM) 7.48 | ||
Enterprise Value to Revenue 8.02 | Enterprise Value to EBITDA 19.06 | Shares Outstanding 445208000 | Shares Floating 444393322 |
Shares Outstanding 445208000 | Shares Floating 444393322 | ||
Percent Insiders 0.23 | Percent Institutions 96.58 |
Analyst Ratings
Rating 4 | Target Price 195.04 | Buy 4 | Strong Buy 10 |
Buy 4 | Strong Buy 10 | ||
Hold 5 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Zoetis Inc
Company Overview
History and Background
Zoetis Inc. was founded in 2013 as a spin-off from Pfizer's animal health division. Pfizer Animal Health existed for over 60 years before the spin-off. Since its IPO, Zoetis has grown organically and through acquisitions to become a leading global animal health company.
Core Business Areas
- Livestock: This segment focuses on products for farm animals, including cattle, swine, poultry, and fish. Products include vaccines, parasiticides, anti-infectives, and other pharmaceuticals.
- Companion Animal: This segment develops and markets products for pets, including dogs, cats, and horses. This includes vaccines, parasiticides, dermatology products, pain management solutions, and other therapies.
- Diagnostics: This segment offers a range of diagnostic products and services for companion and livestock animals.
Leadership and Structure
Zoetis is led by a CEO and a senior management team with expertise in animal health, pharmaceuticals, and finance. The company operates with a global organizational structure, with regional teams responsible for sales and marketing.
Top Products and Market Share
Key Offerings
- Simparica Trio: A monthly chewable tablet for dogs that protects against heartworm disease, fleas, ticks, roundworms, and hookworms. Revenue numbers have not been made public. Competitors include Bravecto (MSD Animal Health) and NexGard (Boehringer Ingelheim).
- Revolution/Stronghold Plus: A topical solution for cats that prevents heartworm disease and treats fleas, ticks, ear mites, and certain worms. Revenue numbers have not been made public. Competitors include Bravecto (MSD Animal Health) and Advantage Multi (Bayer).
- Draxxin: An injectable antibiotic used to treat respiratory diseases in cattle and swine. Revenue numbers have not been made public. Competitors include Baytril (Bayer) and Tylan (Elanco).
- Apoquel: A tablet designed to help control itch in dogs. Competitors include Cytopoint
Market Dynamics
Industry Overview
The animal health industry is experiencing steady growth, driven by increasing pet ownership, rising demand for animal protein, and growing awareness of animal health and welfare. The market is competitive and consolidated with large players who have significant scale and R&D capabilities.
Positioning
Zoetis is a leading player in the animal health industry, with a broad portfolio of products, a strong global presence, and a reputation for innovation. The company's competitive advantages include its scale, R&D capabilities, and strong customer relationships.
Total Addressable Market (TAM)
The global animal health market is projected to reach hundreds of billions of dollars. Zoetis is well-positioned to capture a significant share of this market, given its leading position and diverse portfolio.
Upturn SWOT Analysis
Strengths
- Leading market position
- Broad product portfolio
- Strong R&D capabilities
- Global presence
- Strong customer relationships
Weaknesses
- Dependence on a few key products
- Exposure to regulatory risks
- Potential for generic competition
- Supply Chain Vulnerabilities
Opportunities
- Expanding into new markets
- Developing innovative products
- Acquiring complementary businesses
- Growth in companion animal ownership
- Increasing demand for animal protein
Threats
- Intense competition
- Economic slowdown
- Changes in regulations
- Animal disease outbreaks
- Generic Entry
Competitors and Market Share
Key Competitors
- ELAN
- MRK
- BMY
Competitive Landscape
Zoetis benefits from a large scale, diverse portfolio, and strong customer relationships. Competitors such as Elanco (ELAN) and Merck Animal Health (MRK) also have significant scale and R&D capabilities. Boehringer Ingelheim is also a major player
Major Acquisitions
Jurox
- Year: 2022
- Acquisition Price (USD millions): 500
- Strategic Rationale: Strengthened Zoetisu2019 companion animal portfolio, expanding into high-growth segments and geographies.
Growth Trajectory and Initiatives
Historical Growth: Zoetis has experienced consistent revenue growth over the past several years, driven by a combination of organic growth and acquisitions.
Future Projections: Analyst estimates for future growth vary depending on market conditions and company performance. Analyst reports and financial news sources can provide more information.
Recent Initiatives: Recent initiatives include strategic acquisitions, new product launches, and investments in R&D.
Summary
Zoetis is a strong player in the animal health industry, benefiting from a leading market position, diverse portfolio, and robust R&D. The company has exhibited consistent revenue growth. Potential challenges include competitive pressures, regulatory risks, and dependence on key products. Investors should keep an eye out for competitive pressure and the performance of key products.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Zoetis Investor Relations
- SEC Filings
- Market Research Reports
- Yahoo Finance
- Google Finance
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Zoetis Inc
Exchange NYSE | Headquaters Parsippany, NJ, United States | ||
IPO Launch date 2013-02-01 | CEO & Director Ms. Kristin C. Peck | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 13800 | Website https://www.zoetis.com |
Full time employees 13800 | Website https://www.zoetis.com | ||
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health products in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1950 and is headquartered in Parsippany, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.